Home Featured Page 173

Featured

Latest

The Psychedelic News Feed: January 19 – 25, 2025

“Changes Are Never Linear”: Joost Breeksema on the Human Side of Psychedelic Therapy

Op-Ed: From Psychedelic Prohibition to Psychedelic Public Health

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in...

Joshua White – Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support

Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule;...

PT320 – Anne Philippi – The New Health Club, Intergenerational Trauma,...

PT319 – Kole – Activism and Trust: A Cautionary Tale From...

Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety...

PT318 – Del Jolly, Rashad Evans, and Jake Plummer – Functional...

Update on the Fight for Religious Liberties in Oregon

Psychedelic Research Bulletin: April 2022

PT317 – Jason Grechanik – Ancient Wisdom, Plant Dietas, and The...

Psychedelic Bulletin #101 – Psychedelic R&D in the UK; COMPASS Study...

1...172173174...307 Page 173 of 307

EDITOR PICKS

The Psychedelic News Feed: January 19 – 25, 2025

“Changes Are Never Linear”: Joost Breeksema on the Human Side of...

Op-Ed: From Psychedelic Prohibition to Psychedelic Public Health

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic News Feed: January 19 – 25, 2025

“Changes Are Never Linear”: Joost Breeksema on the Human Side of Psychedelic Therapy

Op-Ed: From Psychedelic Prohibition to Psychedelic Public Health

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in...

Joshua White – Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support

Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule;...

PT320 – Anne Philippi – The New Health Club, Intergenerational Trauma,...

PT319 – Kole – Activism and Trust: A Cautionary Tale From...

DO-Why? The Story of DOI

Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety...

PT318 – Del Jolly, Rashad Evans, and Jake Plummer – Functional...

Update on the Fight for Religious Liberties in Oregon

Psychedelic Research Bulletin: April 2022

PT317 – Jason Grechanik – Ancient Wisdom, Plant Dietas, and The...

Psychedelic Bulletin #101 – Psychedelic R&D in the UK; COMPASS Study...

EDITOR PICKS

The Psychedelic News Feed: January 19 – 25, 2025

“Changes Are Never Linear”: Joost Breeksema on the Human Side of...

Op-Ed: From Psychedelic Prohibition to Psychedelic Public Health

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY